IL165883A0 - Marker genes for determining renal toxicity - Google Patents

Marker genes for determining renal toxicity

Info

Publication number
IL165883A0
IL165883A0 IL16588304A IL16588304A IL165883A0 IL 165883 A0 IL165883 A0 IL 165883A0 IL 16588304 A IL16588304 A IL 16588304A IL 16588304 A IL16588304 A IL 16588304A IL 165883 A0 IL165883 A0 IL 165883A0
Authority
IL
Israel
Prior art keywords
marker genes
renal toxicity
determining renal
determining
toxicity
Prior art date
Application number
IL16588304A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL165883A0 publication Critical patent/IL165883A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL16588304A 2002-07-04 2004-12-20 Marker genes for determining renal toxicity IL165883A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0215509.1A GB0215509D0 (en) 2002-07-04 2002-07-04 Marker genes
PCT/EP2003/007111 WO2004005544A2 (fr) 2002-07-04 2003-07-03 Genes marqueurs

Publications (1)

Publication Number Publication Date
IL165883A0 true IL165883A0 (en) 2006-01-15

Family

ID=9939850

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16588304A IL165883A0 (en) 2002-07-04 2004-12-20 Marker genes for determining renal toxicity

Country Status (10)

Country Link
US (1) US20060008804A1 (fr)
EP (2) EP1925677A3 (fr)
JP (2) JP2005531321A (fr)
CN (1) CN1688715A (fr)
AU (1) AU2003250879B2 (fr)
BR (1) BR0312405A (fr)
CA (1) CA2493860A1 (fr)
GB (1) GB0215509D0 (fr)
IL (1) IL165883A0 (fr)
WO (1) WO2004005544A2 (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60137934D1 (de) 2000-06-16 2009-04-23 Biogen Idec Inc Renale regulatorische elemente und deren verwendung
DK1401869T3 (da) 2001-06-01 2008-04-28 Biogen Idec Inc Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1
SI1585546T1 (sl) 2002-12-30 2008-12-31 Biogen Idec Inc KIM-1 antagonisti in uporaba za moduliranje imunskega sistema
EP1750500B1 (fr) * 2004-05-06 2015-07-08 The Trustees of Columbia University in the City of New York Ngal pour la reduction et l'amelioration des lesions ischemiques et nephrotoxiques
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
NZ555926A (en) * 2004-12-20 2008-11-28 Antibodyshop As Determination of neutrophil gelatinase-associated lipocalin (NGAL) as a diagnostic marker for renal disorders
BRPI0608254A2 (pt) 2005-03-02 2009-12-08 Biogen Idec Inc anticorpos kim-1 para o tratamento de condições mediadas por th2
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
US20070087387A1 (en) 2005-04-21 2007-04-19 Prasad Devarajan Method for the Early Detection of Renal Disease Using Proteomics
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
EP2035835B1 (fr) 2006-05-30 2011-12-28 Antibodyshop A/S Procédés pour évaluer rapidement la gravité d'un traumatisme physique
EP2602624A1 (fr) * 2006-08-07 2013-06-12 Antibodyshop A/S Test de diagnostic pour exclure une importante lésion rénale
CN101680903A (zh) * 2007-03-21 2010-03-24 比奥波托诊断股份公司 肾损伤的诊断试验
EP2479570A3 (fr) 2007-03-26 2012-09-26 Novartis AG Biomarqueurs de sécurité rénale prédictive et signatures de biomarqueur pour surveiller la fonction rénale
US20090104649A1 (en) 2007-06-11 2009-04-23 Garovic Vesna D Markers for preeclampsia
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
WO2009062520A1 (fr) * 2007-11-15 2009-05-22 Bioporto Diagnostics A/S Utilisation diagnostique de formes moléculaires particulières d'un biomarqueur
EP2075343A1 (fr) * 2007-12-21 2009-07-01 Gert Mayer Procédé pour diagnostiquer une maladie progressive
EP2279270B1 (fr) * 2008-04-15 2014-06-18 Oberbauer, Rainer Marqueurs de l'insuffisance rénale aiguë
US7977110B2 (en) 2008-06-02 2011-07-12 Children's Hospital Medical Center Method for distinguishing between kidney dysfunctions
ES2341419B1 (es) * 2008-08-14 2011-05-03 Hospital Clinic I Provincial De Barcelona Wnt1 como biomarcador de daño renal.
CA2742291A1 (fr) * 2008-11-05 2010-05-14 Abbott Laboratories Isoformes proteiques de lipocaline associee a une gelatinase neutrophile (ngal) enrichies a partir d'urine et de cellules d'ovaire de hamster chinois recombinantes (cho), et compositions apparentees, anticorps et procedes d'enrichissement, d'analyse et d'utilisation
JP5752600B2 (ja) 2008-11-10 2015-07-22 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法
CN103439510B (zh) * 2008-11-22 2016-09-14 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
MX2011007624A (es) * 2009-01-19 2011-10-12 Hospices Civils Lyon Metodos para determinar la susceptibilidad de contraer una infeccion nosocomial en el paciente y para establecer el pronostico de la evolucion del sindrome septico.
CN102300875B (zh) * 2009-01-28 2014-07-16 财团法人工业技术研究院 肾病相关的生物标记
WO2011017683A1 (fr) * 2009-08-07 2011-02-10 Rules-Based Medicine, Inc. Méthodes et dispositifs permettant de détecter des lésions rénales
JP5753541B2 (ja) 2009-12-21 2015-07-22 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 抗ｖｅｇｆ治療によって治療された患者におけるタンパク尿の初期マーカー
CN102713632B (zh) 2009-12-23 2015-10-07 希尔氏宠物营养品公司 用于诊断和治疗犬肾脏病症的组合物和方法
WO2011149962A1 (fr) 2010-05-24 2011-12-01 The Trustees Of Columbia University In The City Of New York Proteines ngal mutantes et leurs utilisations
CA2807552A1 (fr) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Acides nucleiques modifies et leurs procedes d'utilisation
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
JP5804629B2 (ja) * 2011-07-29 2015-11-04 株式会社メディクローム 遺伝子発現変動解析による化学物質の毒性評価方法
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP2014530350A (ja) * 2011-09-14 2014-11-17 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 腎臓毒性を評価するための手段及び方法
EP2763701B1 (fr) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Nucléosides, nucléotides et acides nucléiques modifiés, et leurs utilisations
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151663A1 (fr) 2012-04-02 2013-10-10 modeRNA Therapeutics Polynucléotides modifiés pour la production de protéines membranaires
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP3901251B9 (fr) 2012-10-24 2025-06-18 ProKidney Populations de cellules rénales et leurs utilisations
EP2925337B1 (fr) 2012-11-21 2019-07-03 The Trustees of Columbia University in the City of New York Protéines ngal mutantes et leurs utilisations
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
US10420337B2 (en) 2013-03-15 2019-09-24 Lifeline Scientific, Inc. Transporter with a glucose sensor for determining viability of an organ or tissue
JP6297676B2 (ja) 2013-05-06 2018-03-20 日立化成株式会社 標的分子を捕捉するためのデバイス及び方法
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
WO2015153860A1 (fr) * 2014-04-04 2015-10-08 Somalogic, Inc. Biomarqueurs de débit de filtration glomérulaire et leurs utilisations
US10712349B2 (en) 2014-04-15 2020-07-14 The Brigham And Women's Hospital, Inc. Circulating KIM-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney
WO2015160805A1 (fr) * 2014-04-15 2015-10-22 The Brigham And Women's Hospital, Inc. Taux de kim-1 circulant pour la détection de pathologies associées à une lésion ou un cancer du rein
EP3189164B1 (fr) 2014-09-05 2021-11-10 American University Of Beirut Détermination du risque de développement d'une maladie cardiovasculaire par mesure des teneurs urinaires en arn messager de podocine et de néphrine
US10370719B2 (en) * 2014-11-12 2019-08-06 Hitachi Chemical Co., Ltd. Method and device for diagnosing organ injury
CN108271422A (zh) 2015-06-25 2018-07-10 株式会社国际电气通信基础技术研究所 基于器官间串扰系统的预测装置及预测程序
JP6624704B2 (ja) 2015-08-31 2019-12-25 日立化成株式会社 尿路上皮疾患の評価のための分子法
EP4005598A1 (fr) * 2016-03-29 2022-06-01 Karydo Therapeutix, Inc. Procédé de criblage de substances candidates pour un composant actif pour prévenir ou traiter au moins une maladie choisie dans le groupe constitué d'une hypofonction rénale, une maladie rénale chronique et une insuffisance rénale
CN109414504B (zh) 2016-03-29 2022-04-08 无限生物制药公司 药物组合物或食品组合物及评价活性成分体内效果的方法
WO2017216325A1 (fr) * 2016-06-17 2017-12-21 F. Hoffmann-La Roche Ag Essai de dépistage de la néphrotoxicité in vitro
WO2019075411A1 (fr) * 2017-10-12 2019-04-18 Cedars-Sinai Medical Center Biomarqueurs de pronostic et de progression d'une néphropathie chronique

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA951461B (en) * 1994-02-22 1996-01-24 Univ Illinois Genes and genetic elements associated with sensitivity to platimun-based drugs
WO1999037757A1 (fr) * 1998-01-22 1999-07-29 Administrators Of The Tulane Educational Fund Proteine cubiline, sequences d'adn codant la cubiline, et utilisations correspondantes
CA2340589A1 (fr) * 1998-08-28 2000-03-09 Incyte Pharmaceuticals, Inc. Marqueurs de reaction toxicologique
EP1153137A2 (fr) * 1999-02-12 2001-11-14 Phase-1 Molecular Toxicology Inc. Test toxicologique a haut rendement utilisant des organismes et cellules de culture
US20010034023A1 (en) * 1999-04-26 2001-10-25 Stanton Vincent P. Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing
AU1466001A (en) * 1999-11-05 2001-05-14 Phase-1 Molecular Toxicology Methods of determining individual hypersensitivity to an agent
US20020037508A1 (en) * 2000-01-19 2002-03-28 Michele Cargill Human single nucleotide polymorphisms
ATE439453T1 (de) * 2000-06-05 2009-08-15 Genetics Inst Llc Zusammensetzungen, testsätze und methoden zur identifizierung und modulation von typ i diabetes
DE60137934D1 (de) * 2000-06-16 2009-04-23 Biogen Idec Inc Renale regulatorische elemente und deren verwendung
WO2001098539A2 (fr) * 2000-06-21 2001-12-27 Hitachi Chemical Co., Ltd. Marqueurs genetiques destines au cancer du poumon
WO2002006537A2 (fr) * 2000-07-13 2002-01-24 Curagen Corporation Methodes permettant d'identifier des facteurs de protection renaux
US7553644B2 (en) * 2000-07-13 2009-06-30 The Johns Hopkins University School Of Medicine Detection and treatment of polycystic kidney disease
JP2004522411A (ja) * 2000-07-31 2004-07-29 ジーン ロジック インコーポレイテッド 分子毒性学モデリング
DE10056802B4 (de) * 2000-11-14 2005-06-16 Epigenomics Ag Verfahren zur Detektion von Methylierungszuständen zur toxikologischen Diagnostik
CA2440008A1 (fr) * 2001-01-29 2002-08-29 Phase-1 Molecular Toxicology, Inc. Us0204917genes de rats en rapport avec la toxicologie, et leurs utilisations

Also Published As

Publication number Publication date
BR0312405A (pt) 2005-04-26
CA2493860A1 (fr) 2004-01-15
EP1925677A3 (fr) 2008-07-02
CN1688715A (zh) 2005-10-26
WO2004005544A3 (fr) 2004-04-22
EP1925677A2 (fr) 2008-05-28
WO2004005544A2 (fr) 2004-01-15
AU2003250879A1 (en) 2004-01-23
AU2003250879B2 (en) 2007-07-26
GB0215509D0 (en) 2002-08-14
JP2010042019A (ja) 2010-02-25
EP1521847A2 (fr) 2005-04-13
JP2005531321A (ja) 2005-10-20
US20060008804A1 (en) 2006-01-12

Similar Documents

Publication Publication Date Title
GB0215509D0 (en) Marker genes
AU2003294828A8 (en) Specific markers for pancreatic cancer
AU2003281287A8 (en) Toxicity markers
GB0207107D0 (en) Turf image marker
EP1526865A4 (fr) Composes de ciblage de cellules hepatiques
AU304007S (en) Dress-making line marker
GB2394697B (en) Marker pens
GB0225360D0 (en) Genetic markers
IL173923A0 (en) Selection system containing non-antibiotic resistance selection marker
GB0307643D0 (en) Markers
GB2407937B (en) Position locating system
GB2421692B (en) Distance marker
GB0305202D0 (en) Scale inhibitor
GB0326197D0 (en) Molecular marker
GB0223982D0 (en) Marker gene
GB2403931B (en) Marker pens
GB2398877B (en) Scale
GB0307640D0 (en) Markers
IL148158A0 (en) Marker for sign
AU2003900454A0 (en) Dna markers for marbling
GB0303728D0 (en) Toxicity marker
GB0215575D0 (en) Toxicity marker
GB2402367B (en) Book marker
GB0220879D0 (en) Toxicity markers
GB0300928D0 (en) Surrogate markers